Allergy Therapeutics Plc (AGY) Ord GBP0.01

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Allergy Therapeutics trades in line, H1 revenues rise
13 January 2021 09:21
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Wednesday that it was trading in line with expectations, with revenues growing in the first half of the trading year despite...
-
Allergy Therapeutics begins peanut allergy vaccine study
5 January 2021 16:44
(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at...
-
Allergy Therapeutics screens first patients in grass pollen study
26 October 2020 13:37
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of...
-
Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax
3 September 2020 15:31
(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.
-
Allergy Therapeutics revenues grow despite Covid-19 disruption
15 July 2020 09:03
(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.
-
Allergy Therapeutics pleased with invalidation of B301 trial data
9 July 2020 16:26
(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the...
-
Allergy Therapeutics on track to 'significantly' exceed FY expectations
24 June 2020 10:12
(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.
-
Allergy Therapeutics to take 'stepwise approach' to upcoming grass study
26 November 2019 14:15
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further...
-
Allergy Therapeutics earnings set to top expectations
27 June 2019 10:07
(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.
-
Allergy Therapeutics flags positive outcomes from recent treatment trial
20 May 2019 11:00
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous \'Acarovac MPL\' (monophosphoryl lipid A) in patients with...
-
Allergy Therapeutics eyes 2020 start for hay fever inoculation trials
25 April 2019 10:01
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following...
-
Allergy Therapeutics shares plunge after disappointing clinical trial
18 March 2019 08:51
(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of...
Company announcements Announcements
-
Half Year Trading Update 2021 & Notice of Results
13 January 2021 07:00
Allergy Therapeutics
-
Second Price Monitoring Extn
8 January 2021 16:41
Allergy Therapeutics
-
Price Monitoring Extension
8 January 2021 16:36
Allergy Therapeutics
-
Initiation of peanut allergy biomarker study
5 January 2021 07:00
Allergy Therapeutics
-
Director/PDMR Shareholding
14 December 2020 15:58
Allergy Therapeutics
-
Result of Annual General Meeting
8 December 2020 14:42
Allergy Therapeutics
-
Grant of Awards under Long Term Incentive Plan
20 November 2020 13:51
Allergy Therapeutics
-
Director/PDMR Shareholding
20 November 2020 07:00
Allergy Therapeutics
-
Annual Report & Accounts and AGM Notification
10 November 2020 07:05
Allergy Therapeutics
-
Initiation of Grass MATA MPL exploratory study
26 October 2020 07:00
Allergy Therapeutics
-
Holding(s) in Company
12 October 2020 07:00
Allergy Therapeutics
-
Director Dealings and Issue of Equity
9 October 2020 07:00
Allergy Therapeutics
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.